Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sandoz Group Ltd ( (CH:SDZ) ) has shared an update.
Sandoz has secured European Commission marketing authorization for Ranluspec, a ranibizumab biosimilar developed with Lupin for treating neovascular age-related macular degeneration and a range of other retinal vascular disorders. Demonstrating equivalent efficacy and comparable safety to Lucentis, the drug targets conditions affecting millions of patients, with launch planned for the second half of 2026.
The approval reinforces Sandoz’s ambitions in ophthalmology and consolidates its broader biosimilars leadership, following the earlier European launch of Afqlir and its strategy to tap a projected USD 320 billion biosimilar market over the coming decade. Under its partnership with Lupin, Sandoz will hold exclusive commercialization rights for Ranluspec in most EU markets, complementing its separate ranibizumab offering in Germany and potentially broadening access to vision-saving therapies for European patients.
The most recent analyst rating on (CH:SDZ) stock is a Buy with a CHF75.00 price target. To see the full list of analyst forecasts on Sandoz Group Ltd stock, see the CH:SDZ Stock Forecast page.
More about Sandoz Group Ltd
Sandoz Group AG is a Basel-based global leader in affordable medicines and biosimilars, supplying around 1,300 products that range from treatments for common colds to cancer. With more than 20,000 employees of 100 nationalities and 2024 net sales of USD 10.4 billion, the company focuses on expanding access to high-quality generics and biosimilars, generating significant healthcare savings worldwide.
YTD Price Performance: 16.22%
Average Trading Volume: 738,966
Technical Sentiment Signal: Buy
Current Market Cap: CHF29.34B
See more data about SDZ stock on TipRanks’ Stock Analysis page.